Uromigos-Kidney Cancer
Dr. Celeste Simon discusses her career in translational science and kidney cancer at the University of Pennsylvania.
Dr. Laurence Albiges discusses biomarker studies and new combinations and therapies presented at the KCRS23 meeting.
Rachel Giles, MD, PhD, describes her patient data on adjuvant and first line treatments in renal cell carcinoma.
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
Bob Motzer, MD, joins the discussion on IPI/Nivo versus VEGF/PD1 to give his perspective on the recent debate from ASCO 2023.
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
A summary of the renal cancer session of the Conversations & Trending Topics in GU Cancers conference in the Canary Islands.
Monty Pal, MD, FASCO, discusses his recent study on the use of novel CAR T-cell therapy for renal cell carcinoma.
David McDermott, MD, debates the role of ipilimumab for clear cell renal cancer with Uromigos host Brian Rini, MD.
Pavlos Msaouel chats with The Uromigos about his editorial on the results of the recent COSMIC-313 trial.
The Uromigos chat with Dan Shapiro, Assistant Professor of Urologic Oncology, on his work in renal medullary carcinoma.
The Uromigos chat with Scott M. Haake for the second episode of their Rising Star series and discuss his latest project.
The Rising Star series starts with Renee Saliby, a postdoctoral GU oncology research fellow at Dana-Farber Cancer Institute.
Toni Choueiri describes the COSMIC-313 trial on cabozantinib with nivolumab and ipilimumab in advanced or metastatic RCC.
Bernard Escudier, MD, joins The Uromigos to talk about his career development and work in the field of kidney cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.